Jushi (OTCMKTS:JUSHF) vs. AtriCure (NASDAQ:ATRC) Head to Head Survey

Jushi (OTCMKTS:JUSHF) and AtriCure (NASDAQ:ATRC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations for Jushi and AtriCure, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jushi	0	0	1	0	3.00
AtriCure	1	2	6	2	2.82

AtriCure has a consensus target price of $48.71, indicating a potential upside of 77.47%. Given AtriCure’s higher possible upside, analysts clearly believe AtriCure is more favorable than Jushi.

Volatility and Risk

Jushi has a beta of -0.67, indicating that its stock price is 167% less volatile than the S&P 500. Comparatively, AtriCure has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500.

Insider and Institutional Ownership

21.7% of Jushi shares are owned by institutional investors. Comparatively, 99.1% of AtriCure shares are owned by institutional investors. 23.1% of Jushi shares are owned by company insiders. Comparatively, 4.0% of AtriCure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Jushi and AtriCure”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jushi	$262.91 million	0.37	-$68.59 million	($0.36)	-1.35
AtriCure	$534.53 million	2.60	-$11.45 million	($0.10)	-274.50

AtriCure has higher revenue and earnings than Jushi. AtriCure is trading at a lower price-to-earnings ratio than Jushi, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Jushi and AtriCure’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Jushi	-26.90%	N/A	-16.59%
AtriCure	-0.83%	0.29%	0.22%

Summary

AtriCure beats Jushi on 12 of the 15 factors compared between the two stocks.

About Jushi

Jushi Holdings Inc., a vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of cannabis for medical and adult-use markets. The company offers flower, extracts, concentrates, edibles, oil, pre-rolls, tinctures, capsules, softgels, cannabis-infused gummies and ultra-premium chocolate, and topicals products, as well as vaporization devices and cartridges under The Bank, The Lab, Nira+ Medicinals, Sèchè, Tasteology, and Hijinks brands. It is also involved in the bulk wholesale of refined cannabinoids and terpenes. In addition, the company operates medical cannabis dispensaries under the BEYOND/HELLO, Nature’s Remedy, and NuLeaf brands. It markets its products to local dispensaries and large multi-state operators. The company is headquartered in Boca Raton, Florida.

About AtriCure

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.